All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109587" target="_blank" >RIV/00843989:_____/22:E0109587 - isvavai.cz</a>

  • Alternative codes found

    RIV/61988987:17110/22:A2302FTO

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26529" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ajh.26529</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ajh.26529" target="_blank" >10.1002/ajh.26529</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

  • Original language description

    Natural killer (NK) cells are part of a phylogenetically old defense system, which is characterized by its strong cytolytic function against physiologically stressed cells such as tumor cells and virus-infected cells. Their use in the treatment of hematological malignancies may be more advantageous in several ways when compared with the already established T lymphocyte-based immunotherapy. Given the different mechanisms of action, allogeneic NK cell products can be produced in a non-personal based manner without the risk of the formidable graft-versus-host disease. Advanced manufacturing processes are capable of producing NK cells relatively easily in large and clinically sufficient numbers, useable without subsequent manipulations or after genetic modifications, which can solve the lack of specificity and improve clinical efficacy of NK cell products. This review summarizes the basic characteristics of NK cells and provides a quick overview of their sources. Results of clinical trials in hematological malignancies are presented, and strategies on how to improve the clinical outcome of NK cell therapy are discussed.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    American journal of hematology

  • ISSN

    0361-8609

  • e-ISSN

    1096-8652

  • Volume of the periodical

    97

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    16

  • Pages from-to

    802-817

  • UT code for WoS article

    000773282400001

  • EID of the result in the Scopus database

    2-s2.0-85127266476